MAP leaps on up to $900M deal with AZ
Anglo-Swedish drug major AstraZeneca has entered an exclusive worldwide agreement to develop and commercialize Unit Dose Budesonide, US firm MAP Pharmaceuticals' proprietary nebulized formulation of budesonide. The news, which could bring in a total of $900.0 million to the latter, caused MAP's share price to rocket 50% to $6.89 on December 19, 2008.
UDB is being developed by MAP as a potential treatment for pediatric asthma and is currently in Phase III clinical development. The agent has the potential to be nebulized more quickly and at a lower nominal dose than the commercially-available budesonide product.
$40 million upfront
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
| Headless Content Management with Blaze